- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Quartet of biotechs join Nasdaq after stellar IPOs | ||
| 07.08. | TransThera's resistant biliary cancer drug cleared in China | ||
| 07.08. | Google defectors set up AI-based scientific method company | ||
| 07.08. | Third time lucky for Replimune as FDA OKs melanoma drug | ||
| 07.08. | LifeMine gets $263m for transplant drug, and other financings | ||
| 06.08. | Tarsus places $800m wager on Alkeus' Stargardt therapy | ||
| 06.08. | Novo Nordisk wins Netherlands GLP-1 compounding lawsuit | ||
| 06.08. | Takeda's first-in-class narcolepsy drug claims FDA approval | ||
| 06.08. | Senate confirms Erica Schwartz as CDC Director | ||
| 06.08. | FDA clears Moderna's mRNA-based seasonal flu shot | ||
| 05.08. | Sources quash rumours of an AstraZeneca/BMS mega-merger | ||
| 05.08. | UK postcode lottery ends for 'life-changing' cystinosis drug | ||
| 05.08. | Lilly's GLP-1s race away in Q2, though Foundayo falls short | ||
| 05.08. | Cavanaugh to replace Taubert as J&J's pharma head | ||
| 05.08. | Novo fails to shrug off investor concern at Q2 update | ||
| 05.08. | Moderna starts first trial of its Bundibugyo Ebola vaccine | ||
| 04.08. | Pfizer targets $2.5bn more in cost savings | ||
| 04.08. | MSD records one hit, one miss with TL1A drug tulisokibart | ||
| 04.08. | MSD records one win, one miss with TL1A drug tulisokibart | ||
| 04.08. | NICE breast cancer criteria missing patients, claims study | ||
| 04.08. | Pathos AI signs two cancer deals with Alphamab and AZ | ||
| 03.08. | Curium strikes $8bn deal to buy radiopharma rival Lantheus | ||
| 03.08. | CNS-focused Supernus and Indivior agree merger terms | ||
| 03.08. | Sandoz will pay another $480m to settle US antitrust suits | ||
| 03.08. | Sobi's long-serving CEO Guido Oelkers to step down |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.